| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 661.58% | HC Wainwright & Co. | $20 → $16 | Maintains | Buy |
| 09/20/2023 | 851.97% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 09/08/2023 | 851.97% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 08/21/2023 | 709.18% | B of A Securities | $19 → $17 | Maintains | Buy |
| 08/17/2023 | 851.97% | Wedbush | → $20 | Reiterates | Outperform → Outperform |
| 08/14/2023 | 851.97% | HC Wainwright & Co. | $22 → $20 | Maintains | Buy |
| 06/06/2023 | 947.17% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy |
| 05/11/2023 | 947.17% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy |
| 03/23/2023 | 947.17% | HC Wainwright & Co. | → $22 | Reiterates | → Buy |
| 10/11/2022 | 613.98% | UBS | → $15 | Initiates Coverage On | → Buy |
| 07/27/2022 | 947.17% | HC Wainwright & Co. | → $22 | Initiates Coverage On | → Buy |
| 06/13/2022 | 1232.76% | Wedbush | → $28 | Initiates Coverage On | → Outperform |
| 08/25/2021 | 1042.37% | BTIG | → $24 | Initiates Coverage On | → Buy |
| 08/24/2021 | 994.77% | B of A Securities | → $23 | Initiates Coverage On | → Buy |
| 08/24/2021 | 994.77% | Cantor Fitzgerald | → $23 | Initiates Coverage On | → Overweight |
| 08/24/2021 | 1042.37% | Stifel | → $24 | Initiates Coverage On | → Buy |
What is the target price for Rani Therapeutics Hldgs (RANI)?
The latest price target for Rani Therapeutics Hldgs (NASDAQ: RANI) was reported by HC Wainwright & Co. on November 9, 2023. The analyst firm set a price target for $16.00 expecting RANI to rise to within 12 months (a possible 661.58% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rani Therapeutics Hldgs (RANI)?
The latest analyst rating for Rani Therapeutics Hldgs (NASDAQ: RANI) was provided by HC Wainwright & Co., and Rani Therapeutics Hldgs maintained their buy rating.
When is the next analyst rating going to be posted or updated for Rani Therapeutics Hldgs (RANI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rani Therapeutics Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rani Therapeutics Hldgs was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
Is the Analyst Rating Rani Therapeutics Hldgs (RANI) correct?
While ratings are subjective and will change, the latest Rani Therapeutics Hldgs (RANI) rating was a maintained with a price target of $20.00 to $16.00. The current price Rani Therapeutics Hldgs (RANI) is trading at is $2.10, which is out of the analyst's predicted range.